With the FDA’s rapid clearance of teclistamab, treatment options for people with relapsed or resistant multiple myeloma are being increased (Tecvayli).
According to the approval, adults who have had at least four prior therapies—including an immunomodulator, a proteasome inhibitor, and an anti-CD38 antibody—may utilize the bispecific antibody (triple-class refractory disease). The first medication of its kind to receive FDA approval, teclistamab activates the immune system’s defenses against cancer by rerouting T cells through CD3 and the B-cell maturation antigen (BCMA).
With the FDA’s rapid clearance of teclistamab, treatment options for people with relapsed or resistant multiple myeloma are being increased (Tecvayli).
According to the approval, adults who have had at least four prior therapies—including an immunomodulator, a proteasome inhibitor, and an anti-CD38 antibody—may utilize the bispecific antibody (triple-class refractory disease). The first medication of its kind to receive FDA approval, teclistamab activates the immune system’s defenses against cancer by rerouting T cells through CD3 and the B-cell maturation antigen (BCMA).
CRS (cytokine release syndrome) occurred in 72% of patients receiving teclistamab at the recommended dose, neurologic toxicity in 57%, and immune effector cell-associated neurologic illness in 6% of patients. Grade 3/4 neurologic damage occurred in 2.4% of participants and grade 3 CRS in 0.6% of patients. The only way to obtain teclistamab will be through an FDA-mandated risk assessment and mitigation strategy due to the possibility of CRS and neurotoxicity.
